Navigation Links
Vermillion Reports Fourth Quarter and Full Year 2011 Results
Date:3/27/2012

010. The 2010 royalty was reported to the company and recorded in the first quarter of 2011.

Total operating expenses decreased in the fourth quarter of 2011 to $3.9 million from $4.5 million in the same period a year ago. Operating expenses in the fourth quarter of 2011 included $314,000 in non-cash stock-based compensation, as compared to $1.6 million in the same year-ago quarter. Total operating expenses increased in 2011 to $19.4 million from $15.7 million in 2010. Operating expenses in 2011 included $3.3 million in non-cash stock-based compensation, as compared to $4.9 million in 2010. The annual increase was due primarily to increased average headcount in sales and marketing and related costs, higher clinical trial and collaboration costs for the ongoing development of the company's ovarian cancer program and VASCLIR®, as well as an increase in legal fees including those associated with the company's MAS litigation. Research and development expenses for 2011 also included $435,000 for the Correlogic asset acquisition.

Net loss for the fourth quarter was $3.1 million or $(0.21) per share, as compared to $4.0 million or $(0.38) per share in the same year-ago quarter. Net loss for 2010 included $8.6 million in reorganization items and $4.4 million in gains resulting from the exercise and fair value revaluation of common stock warrants. Net loss for 2011 was $17.8 million or $(1.25) per share, as compared to $19.0 million or $(1.83) per share in 2010.

As of December 31, 2011, the company's cash and cash equivalents totaled $22.5 million. The company used $5.0 million in cash from operations during the fourth quarter, including $435,000 for the Correlogic asset acquisition.

Management Commentary"2011 showed substantial expansion in OVA1 tests usage leading to another year of revenue growth for Vermillion," said Gail S. Page, the company's president and chief executive officer. "In fact, more than 3,700 or 11% of the nation's gyne
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Vermillion Sharpens Focus and Streamlines Operations in 2012
2. Vermillion Receives Notice of Allowance for 5th Biomarker Patent Related to Peripheral Artery Disease
3. Vermillion Reports Results for the Second Quarter 2011
4. Vermillion Announces Notice of Allowance for Peripheral Artery Disease (PAD) Patent
5. Vermillion Announces Joining Russell Microcap® Index
6. Vermillion Announces Notice of Allowance for Alzheimer Patent
7. Vermillion Announces the Appointment of Bruce Huebner to its Board of Directors
8. Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011
9. Stephens Initiates Coverage on Vermillion
10. Vermillion Announces Notice of Allowance of Patent for Breast Cancer Biomarkers
11. Vermillion Announces Issuance of European Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  Neurotech Pharmaceuticals, Inc., ... in the multicenter Phase 2 clinical trial of ... treatment of recurrent subfoveal choroidal neovascularization secondary to ... a unique vascular endothelial growth factor (VEGF) receptor ... "This landmark proof-of-concept study will evaluate ...
(Date:9/2/2015)... Calif. , Sept. 2, 2015 Veracyte, ... Bonnie H. Anderson , president and chief executive officer, ... on Wednesday, September 16, 2015 at 10:30 a.m. ET ... The live audio webcast and subsequent replay ... The webcast will be available shortly after conclusion of ...
(Date:9/2/2015)... , September 2, 2015 ... des Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. ... Rare Genomics Institute. Biovista unterstützt mit ... für die Behandlung anderer Krankheiten als denen, für ... Laffoon und sein Team bei der Wylder ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... efficiency of their entire waste to energy process and continue to contribute to ... Major Upgrade , Temarry’s Waste to Energy process has been operating at their ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2Temarry Recycling’s New $100,000 Waste to Energy Renovation 2
... (Nasdaq: AMGN ) today announced that results ... trials evaluating Vectibix® (panitumumab) in combination with chemotherapy (FOLFOX ... metastatic colorectal cancer (mCRC), respectively, were published online in ... "Both studies demonstrated that Vectibix administered with chemotherapy ...
... 4 Reportlinker.com announces that a new market ... Global Soft Tissue Allografts Industry ... report analyzes the worldwide markets for Soft Tissue ... Cartilage Allografts, Meniscus Allografts, and Tendon Allografts. The ...
... Inc., the U.S.-based group company of Shionogi & ... Drug Administration approval of the non-stimulant medication KAPVAY™ ... for the treatment of Attention Deficit Hyperactivity Disorder ... KAPVAY™ is the only formulation of clonidine hydrochloride ...
Cached Biology Technology:Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 2Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 3Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 4Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 5Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 6Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 7Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 8Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 9Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 10Two Pivotal Vectibix® Phase 3 Studies in First and Second-Line Treatment of Metastatic Colorectal Cancer Published in the Journal of Clinical Oncology 11Reportlinker Adds Global Soft Tissue Allografts Industry 2Reportlinker Adds Global Soft Tissue Allografts Industry 3Reportlinker Adds Global Soft Tissue Allografts Industry 4Reportlinker Adds Global Soft Tissue Allografts Industry 5Reportlinker Adds Global Soft Tissue Allografts Industry 6Reportlinker Adds Global Soft Tissue Allografts Industry 7Reportlinker Adds Global Soft Tissue Allografts Industry 8Reportlinker Adds Global Soft Tissue Allografts Industry 9Reportlinker Adds Global Soft Tissue Allografts Industry 10Reportlinker Adds Global Soft Tissue Allografts Industry 11Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 2Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 3Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 4Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 5Shionogi Announces FDA Approval of KAPVAY™ - The First and Only Therapy Approved for Use with Stimulant Medication for the Treatment of ADHD 6
(Date:9/2/2015)... YORK , Sept. 2, 2015 About ... concern for enterprises, banks, government organizations, telecommunication and hospitals ... assets. Keys, identity badges, and numeric keypads are used ... the structure of palm and fingers of an individual, ... Hand geometry scanners with infrared light and reflectors can ...
(Date:9/2/2015)... , Sept. 2, 2015 Security ... concern for enterprises, banks, government organizations, telecommunications, hospitals, ... numeric keypads were previously being used to prevent ... of two-factor authentication, wherein individuals could gain access ... different components, such as hardware devices and numeric ...
(Date:9/2/2015)... 2, 2015 Biometric ... in a system which uses identical human characteristic ... vein, DNA and finger print. Increasing number of ... such system which provides high level of security. ... and tokens are vulnerable to attacks. Furthermore, Biometric ...
Breaking Biology News(10 mins):Global Hand Geometry Biometrics Market 2015-2019 2Global Hand Geometry Biometrics Market 2015-2019 3Global Biometrics Spending Market in the Government Sector 2015-2019 2Global Biometrics Spending Market in the Government Sector 2015-2019 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4
... fish populations leaving them in danger of total collapse, ... measures in place to control fish stocks may not ... research, which is published in today's Nature, involved compiling ... non-exploited fish off the California coast. The research team ...
... Researchers from the University of Pennsylvania School of Veterinary Medicine ... of fish and mammals in the form of a primitive ... system. Their studies link the evolution of the adaptive ... fight infection, to the more primitive innate immunity in fish, ...
... Institut Pasteur has recently shown that the tuberculosis bacillus ... cells. This formidable pathogen is protected against even the ... may remain dormant for years. This discovery, published in ... fighting tuberculosis. Attempts to eradicate the bacillus entirely from ...
Cached Biology News:Commercial fishing causes dangerous fluctuations in fish populations 2'Killer' B cells demonstrate evolutionary link between fish and mammal immune systems 2'Killer' B cells demonstrate evolutionary link between fish and mammal immune systems 3Tuberculosis: The bacillus takes refuge in adipose cells 2
MOUSE ANTI BOVINE WC1:FITC Immunogen: Bovine lymphocytes...
B.D. Hames and D.M. Glover (1996) • This issue covers T-Cell antigen receptor genes; T-Lymphocyte signal transduction; B-Cell activation antibody engineering and the complement system and other ...
...
... DALTsix Gradient Maker, 1. Modular system ... 2-D electrophoresis.Run up to six lab-cast ... cm) simultaneously.Use with 18- or 24-cm ... pre-assembled hinged gel cassettes.Innovative design simplifies ...
Biology Products: